SoluLinK, Inc. Announces IRS Federal Grant Award to Advance its New Multiplexing and Detection Technology for Research and Diagnostics Applications Used for Accelerating Therapeutics Development
Published: Sep 15, 2011
The Qualifying Therapeutic Discovery Project is targeted at therapeutic discovery projects that show a reasonable potential to:
- Result in new therapies to treat areas of unmet medical need or prevent, detect, or treat chronic or acute diseases and conditions,
- Reduce the long-term growth of health care costs in the United States, or
- Significantly advance the goal of curing cancer within 30 years.
Solulink’s proprietary conjugation reagents and easy-to-use linking kits provide unique features and benefits used to link proteins, oligonucleotides, peptides, and antibodies to each other or to a wide range of surfaces including beads, chips, and slides. Solulink markets its products both directly and through distributors and licensing partners worldwide. Solulink is a privately held company located in San Diego, California. For more information, please visit www.solulink.com.
9853 Pacific Heights Blvd. Suite H
San Diego, California 92121